Home West Coast Emeryville, CA Estrella Immunopharma COMPANY
Clinical Phase 2
Our approach is to advance our CD19-Redirected ARTEMIS T Cell programs in relapsed/refractory and high-risk blood cancers first. From company website Source · Oct 13, 2026
Keywords: artemis Non-Hodgkins Lymphoma B-Cell Non-Hodgkin's Lymphoma (NHL) Lymphomas Non-Hodgkin's B-Cell Non-Hodgkin's Lymphoma Large B-Cell Lymphoma Lymphoma, Non-Hodgkin's, Adult Lymphoma Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma HIV Associated Lymphoma CNS Lymphoma High-grade B-cell Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma EB103 Show all 15 keywords
Location: Emeryville, CA · source · Oct 15, 2026
Profile checked Oct 10, 2026
At a glance HQ Emeryville, CA source Region West Coast Stage Clinical Phase 2 Latest trial Phase 1/Phase 2: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma … (Jun 1, 2024) source Raises and deals from press releases Raise Undisclosed round · about $3.35M · announced Jun 3, 2025 Company release ↗ Source quote Jun 3, 2025 · Company release ↗ “Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing Emeryville, California, June 3, 2025 – Estrella Immunopharma, Inc.” From the company’s own releases; this list is partial. All raises and deals
Timeline Jun 3, 2025 Raise Private placement: $3.35M (total, as published), announced Jun 3, 2025. Source: SEC filing. source ↗ Jun 3, 2025 Raise Undisclosed round · about $3.35M source ↗ Jun 1, 2024 Trial start Phase 1/Phase 2: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) source ↗ Upcoming milestones Jul 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · NCT06343311 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $3.4M. Last 2 years.
Jun 3, 2025 Private placement: $3.35M (total, as published), announced Jun 3, 2025. Source: SEC filing. source ↗ Clinical trials (lead sponsor) 1 Record Title Phase Status Start Primary completion NCT06343311 T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2 Recruiting Jun 1, 2024 Jul 31, 2027 (estimated)
